These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2471008)

  • 1. Effect of doxazosin on cholesterol synthesis in cell culture.
    D'Eletto RD; Javitt NB
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S1-4; discussion S4. PubMed ID: 2471008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster.
    Jansen H; Lammers R; Baggen MG; Penders JM; Birkenhäger JC
    Life Sci; 1989; 44(15):1013-7. PubMed ID: 2564614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies with doxazosin on the saturable binding of 125I-LDL by liver in normocholesterolemic mice.
    Nanjee MN; Miller NE
    J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S35-41. PubMed ID: 2447439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin increases low density lipoprotein receptor activity.
    Leren TP
    Acta Pharmacol Toxicol (Copenh); 1985 Mar; 56(3):269-72. PubMed ID: 2861710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster.
    Jansen H; Lammers R; Baggen MG; Birkenhäger JC
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S5-9; discussion S9-10. PubMed ID: 2471016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse.
    Krupp MN; Hoover KW; Valentine JJ
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S11-8; discussion S18-9. PubMed ID: 2471010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
    Jansen H; Birkenhäger JC
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):354-60. PubMed ID: 1720835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of doxazosin on lipid transport in rats and hamsters.
    Ontko JA; Woodside WF
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S31-6; discussions 36-7. PubMed ID: 2471013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL; Taylor AA; Nelson EB
    Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of doxazosin on plasma lipids and atherogenesis: a preliminary report.
    Kowala MC; Nicolosi RJ
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S45-9; discussion S49. PubMed ID: 2471015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
    Foxall TL; Shwaery GT; Stucchi AF; Nicolosi RJ; Wong SS
    Am J Pathol; 1992 Jun; 140(6):1357-63. PubMed ID: 1351367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters.
    Kowala MC; Nunnari JJ; Durham SK; Nicolosi RJ
    Atherosclerosis; 1991 Nov; 91(1-2):35-49. PubMed ID: 1687433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
    Karge WH; Kowala MC; Weiner EJ; Nicolosi RJ
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S25-9; discussion S29-30. PubMed ID: 2471012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/cdJ mice.
    Swindell AC; Valentine JJ
    Am J Cardiol; 1987 May; 59(14):29G-34G. PubMed ID: 2884850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
    Pool JL
    Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of doxazosin and propranolol administration on lipoprotein lipases in cholesterol-fed rats.
    Jansen H; Baggen RG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S16-20. PubMed ID: 2447435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of LDL receptor activity in Hep-G2 cells by a serum factor(s).
    Ellsworth JL; Brown C; Cooper AD
    J Cell Physiol; 1988 May; 135(2):213-23. PubMed ID: 2836440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the lipid response to selective alpha 1-inhibition.
    Dzau VJ
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S50-2; discussion S52. PubMed ID: 2471017
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacotherapeutics of doxazosin.
    Taylor SH
    Am J Med; 1989 Aug; 87(2A):2S-11S. PubMed ID: 2569822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.